METRIC Study Key Eligibility Criteria

Size: px
Start display at page:

Download "METRIC Study Key Eligibility Criteria"

Transcription

1 The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC). Approximately 300 gpnmb positive, metastatic TNBC patients will be enrolled in up to approximately 160 sites within the United States, Canada, Australia and Europe This is an open label, 2-to-1 randomized comparison of glembatumumab vedotin versus an active control, capecitabine (Xeloda ) Treatment Design Patients treated over 21-day cycles Randomized 2-to-1 to receive either: - Glembatumumab vedotin: an intravenous infusion of medication (1.88 mg/kg) on day 1 of each cycle, or - Capecitabine: oral medication (1250 mg/m 2 ) taken twice daily on days 1 through 14 of each cycle Treatment cycles continue as long as the cancer does not progress or until a study physician determines that the patient should stop receiving treatment in the study Tumor assessments conducted at 6-week intervals for 6 months and 9-week intervals thereafter, until documented progression Study Endpoints The primary endpoint for this study is progression free survival (PFS) Secondary endpoints include objective response rate, duration of response, overall survival, safety and pharmacokinetics Exploratory endpoints include quality of life and/or reduction in cancer-related pain, assessed through analgesic use To qualify for the METRIC study, a patient must: Be at least 18 years of age Have been diagnosed with metastatic TNBC with: - Minimal or no expression of estrogen and progesterone receptors (ER/PR); <10% of cells positive by immunohistochemistry - HER2 staining 0 or 1+ by IHC or copy number <4.0 signals/cell by ISH Have documented progression of disease based on radiographic, clinical or pathologic assessment during or subsequent to the last anticancer regimen received Have received 0-2 prior chemotherapy treatments for advanced (locally advanced/recurrent or metastatic) breast cancer Have prior chemotherapy treatment with a taxane and, if clinically indicated, an anthracycline No prior capecitabine Have ECOG performance status of 0-1 Have adequate bone marrow, liver and renal function No progression/recurrence during or within 3 months of completion of neoadjuvant or adjuvant therapy No ongoing neuropathy or other toxicities that are Grade 2 or worse in severity Breast cancer tumors must be confirmed to express gpnmb. This will be determined by submitting a tissue sample from the advanced (locally advanced/recurrent or metastatic) disease setting to a central laboratory for analysis prior to the study entry (~45% positivity rate). If you have patients who have been diagnosed with metastatic triple-negative breast cancer, we hope that you will consider the METRIC study. To learn more about this study, please contact the study investigator listed on the front of this brochure. Glembatumumab Vedotin (CDX-011) in Patients with Metastatic, gpnmb Overexpressing, Triple-Negative Breast Cancer HELP TAKE TRIPLE-NEGATIVE BREAST CANCER TREATMENT OPTIONS IN A NEW DIRECTION CONTACT A STUDY INVESTIGATOR clinicaltrials.gov/ct2/show/nct

2 Glembatumumab Vedotin, an ADC targeting gpnmb in multiple cancers Glembatumumab vedotin (CDX-011) is an investigational, fully human monoclonal antibody-drug conjugate (ADC) designed to release monomethylauristatin E (MMAE) upon internalization into gpnmb-expressing tumor cells. MMAE binds to tubulin, inhibiting mitosis and leading to cell cycle arrest and apoptosis. The compound and its metabolites do not accumulate over time. gpnmb as a TNBC Therapy Target Triple-negative breast cancer (TNBC) represents a disease with substantial molecular heterogeneity.¹ Treatment with standard-of-care is associated with progressive resistance and short survival.² There is great interest in identifying molecular markers that can be targeted for therapeutic intervention.³ The transmembrane protein gpnmb is aberrantly expressed at high levels in a range of cancers including breast cancer. High tumor expression of gpnmb is: - Associated with invasion and metastasis 4 - Correlated with reduced time to progression and survival in breast cancer 3,4 - Implicated as a negative regulator of anti-tumor immune response Three Completed Clinical Studies Studied in more than 250 patients with heavily pre-treated breast cancer and melanoma Patients with TNBC derived greater clinical benefit from glembatumumab vedotin than from standard of care Phase 2 EMERGE study results published (Yardley, et al. J Clin Oncol. 2015) The EMERGE Study, a randomized Phase 2 study in patients with locally advanced or metastatic, gpnmb-positive breast cancer Study Design Examined whether the anti-cancer activity of glembatumumab vedotin is dependent upon gpnmb expression Randomized 124 patients (2-to-1) to glembatumumab vedotin (n=83) or to chemotherapy of the investigator s choice (IC) (n=41) Stratified by gpnmb expression pattern: highexpressing gpnmb in 40% of TNBC samples vs. 21% of all others Glembatumumab vedotin (1.88 mg/kg) was administered by IV infusion over 90 minutes once every three weeks. Up to two dose reductions (to 1.34 or 1.0 mg/kg) were allowed for toxicity. Investigator s choice (IC) consisted of single-agent chemotherapy, and dosing and supportive care were managed per standard practice. Study treatment continued until disease progression or intolerance, and after documented progression, IC-treated patients were permitted to receive glembatumumab vedotin in a crossover treatment phase. Efficacy The primary efficacy endpoint, objective response rate (ORR) of more than 10% for all patients, was not met; however, improvements in progression free (PFS) and overall survival (OS) were observed in TNBC patients with high gpnmb expression. Strong trends towards benefits were seen in all patients with high gpnmb expression, and in some cases were statistically significant. Patients receiving IC alone who crossed over to receive glembatumumab vedotin upon disease progression appeared to represent the better outcomes in the control arm, with a median survival of 12.5 months, as compared to those who did not cross over, with a median of 5.4 months. Similar outcomes observed for all patients on glembatumumab vedotin and IC, without selecting for gpnmb expression Efficacy Measures for Patients with TNBC and High gpnmb Expression Glembatumumab Vedotin Investigator s Choice Chemo Patients n=10 n=6 Overall Survival months Progression Free Survival months HR=0.14, p= HR=0.11, p= Objective Response Rate (ORR) n (%) 4 (40%) 0 Confirmed PR n (%) 1 (10%) 0 Stable Disease or Better n (%) 9 (90%) 1 (17%) ORR per RECIST 1.1, inclusive of response observed at a single time point Safety Adverse events were manageable and consistent with prior studies Rash, neutropenia, fatigue, nausea, vomiting, peripheral neuropathy and alopecia were more frequent in the glembatumumab vedotin arm Hematologic toxicity was less frequent than IC PFS and OS (but not ORR) were prolonged for patients who developed a rash in cycle 1 compared to those who did not; a similar association was observed in a Phase 1/2 melanoma study 5 Summary Patients with TNBC and tumor gpnmb overexpression may potentially derive the greatest benefit from glembatumumab vedotin The identified threshold for high gpnmb expression, 25% of malignant epithelial cells, includes 41% of the screened patients with TNBC (including archived samples) The ongoing pivotal METRIC study is enrolling patients in order to confirm these findings References 1. Cancer Genome Atlas Network. Nature. 2012; 490: Crown, et al. Ann Oncol. 2012; 23:vi56-vi Yardley, et al. J Clin Oncol. 2015; 33(14): Rose, et al. Clin Cancer Res. 2010; 16(7): Ott, et al. J Clin Oncol. 2014; 32(32): Xeloda is a registered trademark of Hoffmann-La Roche, Inc.

3 KEY INCLUSION CRITERIA Patients aged >18 years with mbc TNBC status (ER and PR < 10%; minimal or no expression of HER2) confirmed in advanced setting Documented PD during or subsequent to the last anticancer regimen Overexpression of gpnmb ( 25% of malignant epithelial cells expressing gpnmb, as determined by a central laboratory in at least one tumor obtained in the advanced setting) 0 to 2 prior chemotherapy containing regimens for advanced breast cancer Prior receipt of anthracycline containing chemotherapy in any setting, unless anthracycline therapy is not clinically indicated Prior receipt of taxane containing chemotherapy, in any setting ECOG Performance Status 0 to 1 Life expectancy of 3 months Measurable (target) disease by RECIST 1.1 criteria Resolution of all chemotherapy or radiationrelated toxicities to Grade 1 severity, except for alopecia Adequate bone marrow, liver and renal function See Protocol for Full List of Eligibility Criteria KEY EXCLUSION CRITERIA Progression/recurrence within 3 months of completion of neoadjuvant or adjuvant chemotherapy Baseline neuropathy > Grade 1 Known brain metastases, unless previously treated and asymptomatic for 2 months and not progressive in size or number for 2 months prior to randomization Previously received capecitabine and discontinued due to progressive disease or intolerance Active systemic infection requiring treatment; Infection controlled by oral therapy will not be exclusionary Chronic use of systemic corticosteroids above the physiologic dose within 7 days of enrollment, except for premedication Significant cardiovascular disease Any underlying medical condition that, in the investigator s opinion, will make the trial inappropriate Other malignancy except for treated basal or squamous skin cancer, curatively treated in situ disease, or any other cancers free of disease for 5 years See Protocol for Full List of Eligibility Criteria

4 Glembatumumab Vedotin 1

5 Glembatumumab Vedotin: gpnmb is an Attractive Target gpnmb is aberrantly expressed at high levels in a range of cancers Predominantly intracellular in normal cells May become localized to the cell surface in cancer Associated with the ability of the cancer cell to invade and metastasize Correlated with reduced time to progression and survival in breast cancer TARGET POPULATION 2016 Projected Incidence* Est. % Patients gpnmb Positive Est. # Patients gpnmb Positive All Breast Cancers (invasive) 249,000 ~20% ( 25% expression) 50,000 Metastatic Triple Negative Breast Cancer 20,000 ~40% ( 25% expression) 8,000 Metastatic Melanoma (Stage III/IV unresectable) 20,600 >80% 16,500 Squamous Cell Lung Cancer 54,000 >85% 45,900 Osteosarcoma 800 >60% 500 Head and Neck Cancer 62,000 >40% 25,000 Pancreatic Cancer 53,000 >55% 29,000 Glioblastoma 12,000 >66% 7,900 *Estimated patient numbers are calculated based on American Cancer Society incidence projections for

6 Glembatumumab Vedotin: ADC Targeting gpnmb in Multiple Indications Antibody drug conjugate designed to release the potent cytotoxin MMAE upon internalization into gpnmbexpressing tumor cells Celldex proprietary target and antibody Fully human IgG2 anti-gpnmb monoclonal antibody Toxin and linker licensed from Seattle Genetics; same technology as Adcetris (brentuximab vedotin) MMAE binds to tubulin, inhibiting mitosis and leading to cell cycle arrest and apoptosis Companion diagnostic to detect gpnmb in development 3 Adcetris is a registered trademark of Seattle Genetics, Inc.

7 Glembatumumab Vedotin: Summary of Clinical Experience (completed trials) Three completed clinical studies (n=283, including control; patients treated with glembatumumab vedotin=255) Phase 1/2 unresectable stage III or stage IV melanoma (n=117) 1 Phase 1/2 advanced, heavily pre-treated breast cancers (n=42) 2 Phase 2 EMERGE study in advanced, heavily pre-treated breast cancers (n=124) 3 MTD (Phase 2 dose) was established as 1.88 mg/kg q3w in melanoma study; more frequent dosing regimens (q2/3w and qw) were associated with increased toxicity In these early studies, ORR and PFS at the Phase 2 dose have been favorable for the heavily-pretreated populations studied (advanced melanoma and breast cancer) Although sample sizes are small, patients with tumors expressing higher levels of gpnmb consistently appear to derive greater clinical benefit from glembatumumab vedotin as compared to the entire population of treated patients In both breast cancer studies, the subset of patient with triple negative breast cancer, where treatment options are limited, also appeared to derive greater clinical benefit from glembatumumab vedotin 1. Ott, et al. J Clin Oncol. 2014; (32)32: Bendell, et al. J Clin Oncol. 2014; 32(32): Yardley, et al. J Clin Oncol. 2015; 33(14):

8 Phase 2 EMERGE Study in Metastatic Breast Cancer: Efficacy Measures (ITT) All Patients Triple Negative High gpnmb Expression Triple Negative and High gpnmb Expression Glemba (n=83) IC (n=41) Glemba (n=28) IC (n=11) Glemba (n=23) IC (n=11) Glemba (n=10) IC (n=6) Overall Survival Progression Free Survival Partial Response (PR) [n (%)] Confirmed PR [n (%)] Stable Disease or Better [n (%)] HR=1.37, p=0.20 HR=0.65, p=0.30 HR=0.67, p=0.31 HR=0.14, p= HR=1.19, p=0.42 HR=0.69, p=0.38 HR=0.63, p=0.18 HR=0.11, p= (12%) 5 (12%) 5 (18%) 0 7 (30%) 1 (9%) 4 (40%) 0 5 (6%) 3 (7%) 2 (7%) 0 3 (13%) 1 (9%) 1 (10%) 0 41 (49%) 19 (46%) 17 (61%) 3 (27%) 15 (65%) 3 (27%) 9 (90%) 1 (17%) Responses per RECIST 1.1 Yardley, et al. J Clin Oncol. 2015; 33(14): On target effect clearly demonstrated in targeted patient populations

9 EMERGE: High Tumor gpnmb Expression Correlates with Response Glembatumumab Vedotin Treated Patients Investigator Choice Treated Patients Thresholds of 10% and 25% gpnmb-positive tumor epithelial cells both show significant enrichment of responders The more conservative choice of 25% gpnmb expression was chosen for entry into METRIC Yardley, et al. J Clin Oncol. 2015; 33(14):

10 Glembatumumab Vedotin Safety Profile In breast cancer and melanoma patients, the most frequent ( 20% of patients) treatment-related toxicities were: Rash/alopecia Skin-related AEs were more common/severe in melanoma Rash associated with greater PFS and ORR in melanoma and prolonged PFS/OS in EMERGE breast cancer study Neutropenia Fatigue/anorexia Nausea/vomiting Diarrhea Peripheral neuropathy Glembatumumab vedotin safety profile is consistent with the class of drugs using the same linker and MMAE, including the approved drug Adcetris Glembatumumab vedotin hematologic toxicity may be less frequent/severe Glembatumumab vedotin rash (mild to moderate severity) may be more frequent (compared with agents recently approved for refractory breast cancer 2,3 ) 1. Younes, et al. N Engl J Med. 2010; 363(19): Perez, et al. J Clin Oncol. 25(23): Cortes, et al. Lancet. 2011; 377(9769): Adcetris is a registered trademark of Seattle Genetics. 7

11 RANDOMIZE (2:1) Registration Study Design in gpnmb Over-expressing TNBC (METRIC) Patients with metastatic TNBC overexpressing gpnmb ( 25% tumor cells by IHC) n=300 glembatumumab vedotin 1.88 mg/kg IV Day 1 of 21-day cycles capecitabine (Xeloda ) 1250 mg/m 2 BID Days 1-14 of 21-day cycles Primary: PFS Secondary: ORR DOR OS Stratification: Line of chemotherapy for advanced disease 0-1 vs. 2 PFS after receipt of taxane therapy 6 months vs. PFS > 6 months Prior anthracycline therapy YES / NO Study initiated Dec 2013 Tumor assessments (6 week intervals x 6 months; 9 week intervals thereafter) until documented progression Survival follow-up (12 week intervals) Clinicaltrials.gov Identifier NCT Xeloda is a registered trademark of Genentech. 8

12 METRIC Key Inclusion Criteria Patients with advanced carcinoma of the breast (histologically or cytologically confirmed) gpnmb over-expression ( 25% of tumor epithelial cells positive by IHC) on samples obtained in the setting of advanced disease confirmed/determined at a central laboratory (Clarient) ER and PR negativity defined as ER/PR: <10% of cells positive by IHC HER2 negativity defined according to 2013 ASCO/CAP guidelines Prior receipt of taxane-containing chemotherapy in any setting Prior receipt of anthracycline containing chemotherapy in any setting, unless anthracycline therapy is not clinically indicated in the opinion of the treating investigator 0-2 lines of chemotherapy for advanced disease ECOG performance status 0 to 1 Life expectancy 3 months 9

13 METRIC Key Exclusion Criteria Subjects unable to provide informed consent and/or unable to comply with the study procedures Investigational therapy within 4 weeks before planned start of study treatment Persistent neuropathy > NCI-CTCAE v 4.0 Grade 1 at Randomization Known active brain metastases unless previously treated and asymptomatic for 2 months and not progressive in size or number for 2 months prior to randomization Significant cardiovascular disease 10

Using Glembatumumab Vedotin (CDX-011) and Immunotherapy

Using Glembatumumab Vedotin (CDX-011) and Immunotherapy Using Glembatumumab Vedotin (CDX-011) and Immunotherapy Jeffrey Raizer, M.D., Executive Medical Director-Clinical Science World ADC San Diego September 21, 2017 Forward Looking Statement This communication

More information

2016 Year-End Results and Conference Call. March 14, 2017

2016 Year-End Results and Conference Call. March 14, 2017 2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform

More information

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes

Edith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously

More information

New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD

New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic

More information

A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma

A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma A Phase 2 Study of Glembatumumab Vedotin, an Antibody Drug Conjugate Targeting gpnmb, in Advanced Melanoma Patrick A. Ott, MD, PhD 1, Anna C. Pavlick, DO 2, Douglas B. Johnson, MD 3, Lowell Hart, MD 4,

More information

Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX

Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin

More information

Immunoconjugates in Both the Adjuvant and Metastatic Setting

Immunoconjugates in Both the Adjuvant and Metastatic Setting Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor

More information

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib)

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski

Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,

More information

Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: Keynote 355 Previous Study Return to List

More information

Recent advances in the management of metastatic breast cancer in older adults

Recent advances in the management of metastatic breast cancer in older adults Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the

More information

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany

Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First

More information

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

Science-Based Innovation-Focused ADC Company. Corporate Overview June 2018

Science-Based Innovation-Focused ADC Company. Corporate Overview June 2018 Science-Based Innovation-Focused ADC Company Corporate Overview June 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements

More information

HER2-Targeted Rx. An Historical Perspective

HER2-Targeted Rx. An Historical Perspective HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line

More information

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium

The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive

More information

Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides

Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative

More information

Immune checkpoint blockade in lung cancer

Immune checkpoint blockade in lung cancer Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data

More information

Overcoming resistance to endocrine or HER2-directed therapy

Overcoming resistance to endocrine or HER2-directed therapy Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most

More information

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA

Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

Science-Based Innovation-Focused ADC Company. Corporate Overview August 2018

Science-Based Innovation-Focused ADC Company. Corporate Overview August 2018 Science-Based Innovation-Focused ADC Company Corporate Overview August 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements

More information

Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study

Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens

More information

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in

More information

Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA

Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting

More information

1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016

1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016 Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background

More information

San Antonio Breast Cancer Symposium December 5-9, 2017

San Antonio Breast Cancer Symposium December 5-9, 2017 Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy

More information

LOTUS (NCT ) randomized phase II trial

LOTUS (NCT ) randomized phase II trial Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca

More information

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID

DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;

More information

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar

More information

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015 Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause. CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase

More information

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere ) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program

More information

Targe:ng HER2 in Metasta:c Breast Cancer in 2014

Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER

OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER & OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina

More information

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy

More information

Breast : ASCO Abstracts for Review

Breast : ASCO Abstracts for Review Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal

More information

Targeted Therapies in Melanoma

Targeted Therapies in Melanoma Mutations and Targets Targeted Therapies in Melanoma ckit NRAS

More information

非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和

非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/

More information

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999

More information

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT

ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE

More information

PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!

PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant

More information

Breast cancer treatment

Breast cancer treatment Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;

More information

Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)

Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and

More information

FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018

FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018 FIRST RESULTS OF NEW DATA OF ABRAXANE IN COMBINATION WITH ATEZOLIZUMAB PRESENTED AT ESMO 2018 IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus

More information

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

Amreen Husain, 10 Eric P. Winer, 11 Sylvia Adams, 12 Peter Schmid 13

Amreen Husain, 10 Eric P. Winer, 11 Sylvia Adams, 12 Peter Schmid 13 IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally

More information

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale

More information

New Drug Development in HER2+ Breast Cancer

New Drug Development in HER2+ Breast Cancer New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%

More information

Her 2 Positive Metastatic Breast Cancer

Her 2 Positive Metastatic Breast Cancer Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications

More information

Chemotherapy for Advanced Gastric Cancer

Chemotherapy for Advanced Gastric Cancer Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,

More information

Metronomic chemotherapy for breast cancer

Metronomic chemotherapy for breast cancer Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,

More information

Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer

Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab

More information

Investor Call. May 19, Nasdaq: IMGN

Investor Call. May 19, Nasdaq: IMGN Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not

More information

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,

More information

Emerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ

Emerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms

More information

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care

A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka

More information

Media Release. Basel, 3 June 2012

Media Release. Basel, 3 June 2012 Media Release Basel, 3 June 2012 Roche s targeted investigational breast cancer medicine, trastuzumab emtansine (T-DM1), reduced the risk of cancer worsening or death by 35 percent in pivotal phase III

More information

ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones

ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative

More information

DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA

DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT

More information

Her 2 Positive Advanced Breast Cancer: From Evidence to Practice

Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,

More information

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

ONT-380 and HER2+ Breast Cancer

ONT-380 and HER2+ Breast Cancer ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Post-ASCO 2017 Cancer du sein Triple Négatif

Post-ASCO 2017 Cancer du sein Triple Négatif Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination

More information

Recent Therapeutic Advances for Thoracic Malignancies

Recent Therapeutic Advances for Thoracic Malignancies Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation

More information

June 2009 Breast Committee CALGB 40502

June 2009 Breast Committee CALGB 40502 CALGB 40502/CTSU 40502 A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nabpaclitaxel or ixabepilone combined with bevacizumab as first-line therapy for locally

More information

Cancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable

Cancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data

More information

Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline

Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline Rabab Mahmoud and Omnia Abd-elfattah Clinical Oncology Department,

More information

Innovations In The Management Of

Innovations In The Management Of Innovations In The Management Of HER2+ Breast Cancer Dr. Sandeep Goyle Consultant Medical Oncologist Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai, India Introduction - Self

More information

First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study

First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,

More information

Patient Selection: The Search for Immunotherapy Biomarkers

Patient Selection: The Search for Immunotherapy Biomarkers Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic

More information

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

Checkpoint Inibitors for Bladder Cancer

Checkpoint Inibitors for Bladder Cancer Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,

More information

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015 Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant

More information

Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer

Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer. Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor

More information

RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet

RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive

More information

Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer

Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)

More information

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008 Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

A vision for HER2 future

A vision for HER2 future School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm

More information